IDEXX EVP exercises options for 197 shares

IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026.

Rhea-AI Filing Summary

IDEXX Laboratories executive Sharon E. Underberg, EVP, GC & Corporate Secretary, exercised an incentive stock option on March 3, 2026. The option conversion resulted in 197 shares of common stock at a transaction price of 505.5300 per share, bringing her direct common stock holdings to 7,137.654 shares.

The incentive stock option right-to-buy covered 197 shares and, following the exercise, showed 0 derivative shares remaining. A footnote states the option grant to buy issuer common stock vested on February 14, 2026, indicating this was a scheduled equity award exercise.

Insider Trade Summary

197 shares exercised/converted

Exercise 2 txns

Insider Underberg Sharon E.

Role EVP, GC & Corporate Secretary

Type	Security	Shares	Price	Value
Exercise	Incentive Stock Option (right-to-buy)	197	$0.00	$0.00
Exercise	Common Stock	197	$505.53	$100K

Holdings After Transaction: Incentive Stock Option (right-to-buy) — 0 contracts (Direct); Common Stock — 7,137.654 shares (Direct)

Footnotes (2)

1. F1. Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.
2. F2. Not applicable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IDEXX (IDXX) executive Sharon E. Underberg report on this Form 4?

Sharon E. Underberg reported exercising an incentive stock option on March 3, 2026, converting 197 derivative rights into 197 shares of IDEXX common stock. This routine equity award transaction increased her directly held common stock position to 7,137.654 shares following the exercise.

How many IDEXX (IDXX) shares were acquired through the option exercise?

The filing shows 197 shares of IDEXX common stock were acquired through a derivative exercise on March 3, 2026. The corresponding incentive stock option for 197 shares was fully exercised, leaving zero derivative shares remaining after the transaction according to the reported totals.

What was the reported transaction price per IDEXX (IDXX) share?

For the common stock line, the transaction price per share was reported as 505.5300. This value applies to the 197 shares of IDEXX common stock received upon exercising the incentive stock option, as disclosed in the non-derivative security transaction details for March 3, 2026.

What position does Sharon E. Underberg hold at IDEXX (IDXX)?

Sharon E. Underberg is listed as an officer of IDEXX, serving as EVP, GC & Corporate Secretary. This indicates she is a senior executive with legal and corporate governance responsibilities, which is why her equity transactions must be reported on Form 4 as an insider.

When did the IDEXX (IDXX) stock option exercised by Underberg vest?

A footnote states the option was a grant to buy IDEXX common stock that vested on February 14, 2026. The reported exercise on March 3, 2026, occurred after this vesting date, indicating it was the use of previously vested incentive stock option rights.

How many IDEXX (IDXX) common shares does Underberg own after this transaction?

After the March 3, 2026 transaction, Sharon E. Underberg is reported to hold 7,137.654 shares of IDEXX common stock directly. This total reflects her position following receipt of 197 new common shares from the exercise and conversion of the incentive stock option.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:01 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Underberg Sharon E.

(Last) (First) (Middle)

ONE IDEXX DRIVE

(Street)

WESTBROOK ME 04092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC & Corporate Secretary

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		197	A	$505.53	7,137.654	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right-to-buy)	$505.53	03/03/2026		M			197	(1)	02/13/2032	Common Stock	197	(2)	0	D

Explanation of Responses:

1. Grant of option to buy shares of Issuer common stock that vested on February 14, 2026.

2. Not applicable.

Remarks:

	/s/ Lily J. Lu, Attorney-in-Fact for Sharon E. Underberg	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.